Loading…
Atrium Therapeutics, Inc. is projected to rise to $11.36 by 2027, a 0% move from its current price of $11.35. RNA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $11.13 | $11.35 | $11.57 | +0.01% |
| Aug 4 | $11.05 | $11.35 | $11.66 | +0.01% |
| Aug 5 | $10.98 | $11.35 | $11.74 | +0.02% |
| Aug 6 | $10.92 | $11.35 | $11.80 | +0.02% |
| Aug 7 | $10.88 | $11.35 | $11.85 | +0.03% |
| Aug 8 | $10.83 | $11.35 | $11.90 | +0.04% |
| Aug 9 | $10.79 | $11.35 | $11.95 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.79 | $11.35 | $11.95 | +0.04% |
| Week 2 | $10.57 | $11.36 | $12.21 | +0.09% |
| Week 3 | $10.41 | $11.36 | $12.41 | +0.13% |
| Week 4 | $10.27 | $11.37 | $12.59 | +0.17% |
| Week 5 | $10.15 | $11.37 | $12.75 | +0.22% |
| Week 6 | $10.05 | $11.38 | $12.89 | +0.26% |
| Week 7 | $9.95 | $11.38 | $13.03 | +0.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Atrium Therapeutics, Inc. is a biopharmaceutical company focusing on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. Its development-stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
The company has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Atrium Therapeutics, Inc. (RNA) operates in the Healthcare sector as a biopharmaceutical company focused on RNA therapeutics for heart conditions. The current price is $11.18 and the market capitalization is $191.24M.
Its market rank is 3822. The forecast implies a long-run price path with upside potential, including a 2026 average at $11.18 and a 2050 maximum at $83.83, with varying annual returns across the horizon.
A major floor 15.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.5% away) — a key level to hold.
The nearest ceiling, 20.3% above — a clean break opens room to run.
A major ceiling 28.1% above — clearing it would confirm fresh momentum.
Key RNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.41 | Sell | $11.45 | Sell |
| MA 10 | $11.67 | Sell | $11.66 | Sell |
| MA 20 | $12.14 | Sell | $11.98 | Sell |
| MA 50 | $12.48 | Sell | $12.46 | Sell |
| MA 100 | $12.96 | Sell | $12.95 | Sell |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.11 | Neutral |
| Stoch RSI (14) | 34.56 | Neutral |
| CCI (20) | -107.44 | Sell |
| Williams %R (14) | -84.82 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | -7.72 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 15.18 | Buy |
| TRIX (15) | -0.32 | Sell |
| Awesome (5,34) | -1.07 | Sell |
| Ultimate (7,14,28) | 28.68 | Buy |
| Momentum (10) | -0.80 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 11.21 | Buy |
| ADX (14) | 19.33 | Neutral |
| ATR (14) | 0.23 | Info |
The 30-day technical picture is BEARISH with an RSI14 of 30. The SMA50 is $12.54, and the price has a nearby support at $11.18 and resistance at $13.65. The 30-day price range runs from $9.83 to $12.72. Annualized volatility is 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.18 | $11.35 | $13.84 | 0% | Neutral | |
| $9.02 | $11.36 | $15.17 | 0% | Neutral | |
| $9.71 | $12.61 | $17.51 | +11% | Neutral | |
| $11.25 | $14.97 | $21.44 | +32% | Bullish | |
| $11.44 | $15.57 | $22.88 | +37% | Bullish | |
| $11.34 | $15.75 | $23.66 | +39% | Bullish | |
| $11.51 | $16.27 | $24.94 | +43% | Bullish | |
| $11.48 | $16.52 | $25.79 | +46% | Bullish | |
| $12.86 | $18.81 | $29.85 | +66% | Bullish | |
| $14.20 | $21.11 | $34.01 | +86% | Bullish | |
| $17.19 | $27.48 | $47.23 | +142% | Bullish | |
| $25.71 | $46.58 | $87.89 | +310% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $11.18 | $11.35 | $13.58 | +0.00% |
| September 2026 | $9.45 | $11.20 | $13.66 | -1.34% |
| October 2026 | $9.56 | $11.41 | $14.08 | +1.93% |
| November 2026 | $9.52 | $11.43 | $14.22 | +0.12% |
| December 2026 | $9.14 | $11.03 | $13.84 | -3.52% |
Click any year to see its month-by-month RNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RNA could reach as high as $13.84, with a base case around $11.35 and support toward $11.18 — roughly 0% from $11.35. Price action looks broadly range-bound.
Expect RNA to range from $9.02 to $15.17 through 2027. The $11.36 average target implies a 0% move from current prices. That is up 0% on the projected 2026 average. A consolidation phase looks the most probable path here.
The RNA price prediction for 2028 points to an average of $12.61 (low $9.71, high $17.51) — a potential gain of +11% on today's $11.35. Price action looks broadly range-bound.
In 2029, RNA is projected to trade between $11.25 and $21.44, averaging $14.97 — a potential gain of +32% from today's $11.35. That is up +19% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Atrium Therapeutics, Inc.'s 2030 outlook centres on $15.57, within a $11.44 to $22.88 range. That is up +4% on the projected 2029 average. That marks a +37% change versus current levels. Momentum favours further upside here.
By 2031, RNA could reach as high as $23.66, with a base case around $15.75 and support toward $11.34 — roughly +39% from $11.35. Buyers look set to stay in control over this stretch.
Expect RNA to range from $11.51 to $24.94 through 2032. The $16.27 average target implies a +43% move from current prices. That is up +3% on the projected 2031 average. Momentum favours further upside here.
The RNA price prediction for 2033 points to an average of $16.52 (low $11.48, high $25.79) — a potential gain of +46% on today's $11.35. Buyers look set to stay in control over this stretch.
In 2034, RNA is projected to trade between $12.86 and $29.85, averaging $18.81 — a potential gain of +66% from today's $11.35. That is up +14% on the projected 2033 average. Momentum favours further upside here.
Atrium Therapeutics, Inc.'s 2035 outlook centres on $21.11, within a $14.20 to $34.01 range. That is up +12% on the projected 2034 average. That marks a +86% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, RNA could reach as high as $47.23, with a base case around $27.48 and support toward $17.19 — roughly +142% from $11.35. Momentum favours further upside here.
Expect RNA to range from $25.71 to $87.89 through 2050. The $46.58 average target implies a +310% move from current prices. That is up +69% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in RNA today (≈ 88.105727 RNA) could be worth
$4,103.95
+$3,103.95 (+310%) by 2050 · US Dollar
Based on the average projected RNA price of $46.58 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNAwould be worth at today's price.
$1,000 invested in RNA on Feb 27, 2026 (≈ 67.79661 RNA) would be worth
$769.49
-$230.51 (-23.1%) today · 0.77× · US Dollar
Based on a RNA entry price of $14.75 vs. today's $11.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.49 | $987.82 | -1.2% |
| 1 month ago | $13.3 | $853.38 | -14.7% |
| 3 months ago | $13.43 | $845.12 | -15.5% |
| All time ago | $14.75 | $769.49 | -23.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNA forecast.
Our base-case forecast reaches $23.00 around 2040.
Implied market cap at $23.00: $393.43M
The multi-year forecast shows a bullish trajectory starting in the late 2020s, with the 2026 average at $11.18 and a 2026 max of $13.59 (ROI 0%). By 2027 the average is $11.16 with a max of $14.93 (ROI -0.2%), and by 2028 the average reaches $12.28 (max $17.10; ROI 9.8%). The path becomes more pronounced in 2029 (avg $14.52; max $20.86; ROI 29.9%) and 2030 (avg $15.14; max $22.33; ROI 35.4%), continuing through 2040 (avg $26.17; max $45.23; ROI 134.1%) and reaching a 2050 forecast (avg $44.13; max $83.83; ROI 294.7%).
The sentiment for 2029 onward is BULLISH, with higher upside in the later years. These are estimates, not guarantees, and market conditions can change. Potential drivers and risks are reflected in the year-by-year numbers and the shift from NEUTRAL to BULLISH over time.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $11.09, an avg of $15.14, and a max of $22.33 with an ROI of 35.4% and a BULLISH sentiment.
The forecast indicates NEUTRAL in 2026 and 2027, then NEUTRAL again in 2028, followed by a BULLISH outlook from 2029 onward, with the longest-horizon ROI reaching 294.7% by 2050.
Yes—the forecast maximum by 2050 is $83.83, so $50 is within the projected upside.
Min $11.18, avg $11.18, max $13.59; ROI 0; sentiment NEUTRAL.
Current price $11.18; market cap $191.24M.
Atrium Therapeutics, Inc. Community Discussion
0Share your Atrium Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.